FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO ® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD
RARITAN, N.J., August 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded peripheral artery disease (PAD) indication for the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization (LER) due to symptomatic PAD. The approval is based on data from the Phase 3 VOYAGER PAD study. With this approval, XARELTO® is the first and only therapy indicated to help reduce the risks of major cardiovascular (CV) events in patients with coronary artery disease (CAD) and major thrombotic vascular events, such as myocardial infarction, ischemic stroke, acute limb ischemia, and major amputation of a vascular etiology, in patients with PAD, including patients who have recently undergone LER due to symptomatic PAD. CLICK TO TWEET: #BREAKINGNEWS: @US_FDA approves expanded #PeripheralArteryDisease #PAD indication for @JanssenUS treatment, evolving current standard of care for #PAD patients & how long-term prevention of persistent #bloodclot related events are managed. Learn more: bit.ly/33sm1yt“For more than 20 years, many physicians have used dual antiplatelet therapy after lower extremity revascularization due to symptomatic PAD with limited data to support efficacy and safety in this setting. Now, the VOYAGER PAD and COMPASS clinical studies have demonstrated the utility of d...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
More News: African Health | Allergy & Immunology | Anesthesia | Anesthesiology | Antiphospholipid Syndrome | Aspirin | Atrial Fibrillation | Babies | Babies Heart Conditions | Back Pain | Bleeding | Brain | Breastfed | Cancer & Oncology | Cardiology | Cardiovascular | Cardiovascular & Thoracic Surgery | Child Development | Children | Chronic Pain | Clinical Trials | Clopidogrel | Complementary Medicine | Conferences | Cough | Coumadin | COVID-19 | Dentistry | Diabetes | Diabetes Type 2 | Education | Emergency Medicine | Endocrinology | Epistaxis (Nosebleeds) | Food and Drug Administration (FDA) | Grants | Headache | Health Management | Heart | Heart Attack | Heart Transplant | Heart Valve Disease | Heart Valve Surgery | Heart Valves | Herbs | Hospitals | Hughes Syndrome | Hypertension | Incontinence | Infectious Diseases | Ischemic Stroke | Kidney Transplant | Learning | Legislation | Liver | Liver Transplant | Lung Transplant | Men | Milk | Neurology | Neuroscience | Neurosurgery | Pain | Pain Management | Partnerships | Peripheral Vascular Disease (PVD) | Pharmaceuticals | Plavix | Pregnancy | Profits and Losses | Pulmonary Hypertension | Pulmonary Thromboembolism | Science | Smokers | Sodium | Stroke | Study | Thrombosis | Universities & Medical Training | Urology & Nephrology | Vaccines | Vitamin A | Vitamins | Warfarin | Warnings